Amgen Lays Out Plans For Rare Disease Portfolio Growth

Ex-US Push, Subcutaneous Dosing For Tepezza

 
• By Mandy Jackson

Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase. 

Male red plastic toy businessman silhouette wooden crowd figure background closeup
Rare disease is one of four pillars for Amgen besides general medicine, inflammation and oncology • Source: Shutterstock

More from Rare Diseases

More from Scrip